Moderate to severe rheumatoid arthritis
Conditions
Interventions
No- response group:None
Sponsors
Suqian First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Be able to actively cooperate with this study and sign the informed consent; 2. Aged 18-70 years old (including 18 and 70 years old); 3. RA patients (diagnostic criteria referred to 1987 ACR classification criteria) and DAS28>3.2 4. Long-term residence at the trial site (at least 6 months) 5. Had not received adalimumab for 10 weeks before dosing 6. Adequate organ function (1) Bone marrow function: 1) hemoglobin >=100 g/L 2) absolute neutrophil count >= 1.5×109/L 3) white blood cell >= 3.0×109/L 4) platelet count >= 100×109/L (2) Liver function (based on the normal value of clinical trial center) : 1) Serum bilirubin = 60 ml/min/1.73m2 or serum creatinine <= 1.5× upper limit of normal value (ULN)
Exclusion criteria
Exclusion criteria: 1.Be pregnant; 2.Allergic to any component of adalimumab injection; 3.Presence of active infection (such as active tuberculosis), including local infection; 4.Patients with malignant tumors; 5.Moderate to severe heart failure; 6.Received live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DAS28-CRP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical disease activity index (CDAI); | — |
Countries
China
Contacts
Public ContactJin Xin
Suqian First Hospital
Outcome results
None listed